GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: BMS-986449 is a molecular glue class molecule. It promotes degradation of the transcription factors IKZF2 and IKZF4 (Helios and Eos respectively, which are involved in suppression of T cell mediated antitumour responses in the tumour microenvironment) via engagement with the cereblon E3 ubiquitin ligase system. BMS-986449 is proposed to promote antitumour immunity [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
BMS-986449 has advanced to clinical evaluation, for the treatment of advanced solid tumours. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05888831 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Phase 1/Phase 2 Interventional | Bristol-Myers Squibb |